This single-center single-arm, open-label prospective clinical trial aimed to evaluate the efficacy and safety of entinostat combined with chemotherapy as second-line therapy for unresectable locally advanced or metastatic bladder cancer.
Histopathologic confirmed unresectable advanced or metastatic bladder cancer, except for those with squamous differentiation, glandular differentiation or both;
Failure of first-line treatment;
There is at least one measurable lesion according to RECIST 1.1;
Archived tumor tissue samples or tumor biopsies must be provided;
Patients who received platinum-based chemotherapy after failure of first-line treatment;
Patients who received platinum-based chemotherapy withnin a 24 month before this trial;
Those who have received other anti-tumor treatment or participated in other clinical studies within 4 weeks before the start of the study, or have not recovered from the last toxicity (except grade 2 hair loss and grade 1 neurotoxicity);
Concomitant disease such as uncontrolled hypertension or diabetes, renal inadequacy, myocardial infarction, severe angina;